Abstract A030: 2X-121, a novel, dual inhibitor of PARP and tankyrase, shows promising clinical benefit in a phase 2 trial in advanced, recurrent ovarian cancer patients (NCT#03878849)
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Fernanda Musa, Steen Knudsen, Thomas Jensen, Annette Nielsen, Peter Gimsing, Anker Hansen, Mogens Winkel Madsen, Jose Iglesias, Jeremy Graff, Kathleen Moore
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4414349017
Cites:
Cited by:
Related to: